JC05 Rec'd PCT/PTO 0 5 0 CT 2005 10/551964 PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q89135

Kunio YASUNAGA, et al

Appln. No.: National Stage of PCT/JP2004/007692

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: October 5, 2005 Examiner: Unknown

For: METHOD OF SCREENING ANTIOBESITY AGENTS AND ANIMAL MODEL OF

**OBESITY** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

JC05 Rec'd PCT/PTO 0 5 OCT 2005

10/551964

INFORMATION DISCLOSURE STATEMENT Appln. No.: National Stage of PCT/JP2004/007692

Attorney Docket No. Q89135

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith English-language version of a

Communication from a foreign patent office in a counterpart application citing such documents

(International Search Report for PCT/JP2004/007692 dated September 14, 2004), indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373

CUSTOMER NUMBER

Date: October 5, 2005

2

JCO5 Rec'd PCT/PTO MODE POT SELECTED (06-03)

			JUUD NEU U PUI	Worth feb 61 dy 2 B d l y 2 B (00-0		
			Complete if Known			
Substitute for Form 1449 A & B/PTO		Application Number	National Stage of			
INFORMATION DISCLOSURE			Confirmation Number	Unknown		
STATEMENT BY APPLICANT		Filing Date	October 5, 2005			
			First Named Inventor	Kunio YASUNAGA		
(us	e as many sheets	s as necessary)	Art Unit	Unknown		
			Examiner Name			
Sheet	1	of 1	Attorney Docket Number	Q89135		

		Document N	U.S. Document Number		
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
	_	US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Cite	Foreign Patent Document			Publication Date	Name of Patentee or		
Initials*	No.1	Country Code <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
	-	JP	2000-300263	Α	10/31/2000	HELIX RESEARCH INSTITUTE	
		wo	99/15653	A1	04/01/1999	GENENTECH, INC.	
·							

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		Y. OIKE, ET AL, "ANGIOPOIETIN-RELATED GROWTH FACTOR (AGF) PROMOTES EPIDERMAL PROLIFERATION, REMODELING, AND REGENERATION", PROC. NATL. ACAD. SCI. USA, Vol. 100, 2003, pages 9494-9499			

Examiner Signature	Date Co.	nsidered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.